| Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes JP Frías, MJ Davies, J Rosenstock, FC Pérez Manghi, L Fernández Landó, ... New England Journal of Medicine 385 (6), 503-515, 2021 | 1274 | 2021 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1217 | 2019 |
| Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial J Rosenstock, C Wysham, JP Frías, S Kaneko, CJ Lee, LF Landó, H Mao, ... The Lancet 398 (10295), 143-155, 2021 | 772 | 2021 |
| Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical … TA Wadden, TS Bailey, LK Billings, M Davies, JP Frias, A Koroleva, ... Jama 325 (14), 1403-1413, 2021 | 729 | 2021 |
| Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator … JP Frias, MA Nauck, J Van, ME Kutner, X Cui, C Benson, S Urva, ... The Lancet 392 (10160), 2180-2193, 2018 | 717 | 2018 |
| Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial SA Harrison, MR Bashir, CD Guy, R Zhou, CA Moylan, JP Frias, ... The Lancet 394 (10213), 2012-2024, 2019 | 689 | 2019 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 567 | 2019 |
| Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial AM Jastreboff, LM Kaplan, JP Frías, Q Wu, Y Du, S Gurbuz, T Coskun, ... New England Journal of Medicine 389 (6), 514-526, 2023 | 500 | 2023 |
| Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised … B Ludvik, F Giorgino, E Jódar, JP Frias, LF Landó, K Brown, R Bray, ... The Lancet 398 (10300), 583-598, 2021 | 491 | 2021 |
| Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, ... The Lancet 398 (10313), 1811-1824, 2021 | 490 | 2021 |
| Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial WT Garvey, RL Batterham, M Bhatta, S Buscemi, LN Christensen, JP Frias, ... Nature medicine 28 (10), 2083-2091, 2022 | 456 | 2022 |
| Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy … JP Frías, C Guja, E Hardy, A Ahmed, F Dong, P Öhman, SA Jabbour The lancet Diabetes & endocrinology 4 (12), 1004-1016, 2016 | 456 | 2016 |
| Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial WT Garvey, JP Frias, AM Jastreboff, CW le Roux, N Sattar, D Aizenberg, ... The Lancet 402 (10402), 613-626, 2023 | 327 | 2023 |
| The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes JP Frias, EJ Bastyr, L Vignati, MH Tschoep, C Schmitt, K Owen, ... Cell Metabolism 26 (2), 343-352. e2, 2017 | 304 | 2017 |
| More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head … J Rosenstock, A Cheng, R Ritzel, Z Bosnyak, C Devisme, AMG Cali, ... Diabetes care 41 (10), 2147-2154, 2018 | 271 | 2018 |
| Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial B Ludvik, JP Frías, FJ Tinahones, J Wainstein, H Jiang, KE Robertson, ... The lancet Diabetes & endocrinology 6 (5), 370-381, 2018 | 271 | 2018 |
| Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial LJ Aronne, N Sattar, DB Horn, HE Bays, S Wharton, WY Lin, NN Ahmad, ... Jama 331 (1), 38-48, 2024 | 268 | 2024 |
| Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis SA Harrison, G Neff, CD Guy, MR Bashir, AH Paredes, JP Frias, Z Younes, ... Gastroenterology 160 (1), 219-231. e1, 2021 | 257 | 2021 |
| Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b … I Lingvay, AM Catarig, JP Frias, H Kumar, NL Lausvig, CW le Roux, ... The lancet Diabetes & endocrinology 7 (11), 834-844, 2019 | 246 | 2019 |
| Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation YT Kruszynska, DS Worrall, J Ofrecio, JP Frias, G Macaraeg, JM Olefsky The Journal of Clinical Endocrinology & Metabolism 87 (1), 226-234, 2002 | 226 | 2002 |
